BioPharma Resources

Drug Trial Radar · NCT07525206

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 990 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

990

Planned (sponsor's estimate)

Start

May 22, 2026

Primary completion

May 2029

Study completion Mar 2030

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Apr 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine and tipiracil) plus bevacizumab in adult participants with refractory metastatic colorectal cancer (mCRC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants will then be randomized into 2 groups called treatment arms. One group will receive telisotuzumab adizutecan with bevacizumab in different doses. Another group will receive standard of care (SOC), trifluridine and tipiracil (LONSURF), with Bevacizumab. Up to approximately 990 adult participants with refractory mCRC, will be enrolled in the study in approximately 125 sites globally. In this Phase 3, one of two groups will receive doses of Intravenous (IV) telisotuzumab adizutecan + bevacizumab and other group will receive oral SOC of trifluridine/tipiracil (LONSURF)+ Intravenous (IV) bevacizumab. The study will run for a duration of approximately of 36 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Conditions

  • Colorectal Cancer

Interventions

  • Telisotuzumab adizutecanDrug

    Intravenous (IV)

  • BevacizumabDrug

    Intravenous (IV)

  • Trifluridine/TipiracilDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 3: Objective Response (OR) as assessed by Blinded Independent Central Review (BICR)Time frame: Up to Approximately 15 Months
  2. Phase 3: Overall Survival (OS)Time frame: Up to Approximately 36 Months

Locations

91 sites in 11 countries. Site status is shown where the registry gives one.

  • City Of Hope - Phoenix /ID# 279450

    Goodyear, Arizona · Recruiting

  • Highlands Oncology Group - Springdale /ID# 279444

    Springdale, Arkansas · Recruiting

  • City of Hope National Medical Center /ID# 279449

    Duarte, California · Recruiting

  • Rocky Mountain Cancer Centers - Aurora /ID# 280112

    Aurora, Colorado · Recruiting

  • Yale University School of Medicine /ID# 279373

    New Haven, Connecticut · Recruiting

  • Moffitt Cancer Center /ID# 279325

    Tampa, Florida · Recruiting

  • City Of Hope - Atlanta /ID# 280017

    Newnan, Georgia · Recruiting

  • University of Chicago Medical Center /ID# 279365

    Chicago, Illinois · Recruiting

  • Saint Lukes Hospital of Kansas City /ID# 279513

    Kansas City, Missouri · Recruiting

  • Astera Cancer Care /ID# 279532

    East Brunswick, New Jersey · Recruiting

  • Northwell Health Center for Advanced Medicine. /ID# 279590

    Lake Success, New York · Recruiting

  • Duke University Medical Center /ID# 279322

    Durham, North Carolina · Recruiting

  • Oncology Hematology Care - Blue Ash /ID# 280143

    Cincinnati, Ohio · Recruiting

  • Compass Oncology - Rose Quarter /ID# 280127

    Portland, Oregon · Recruiting

  • Texas Oncology - Abilene - Antilley Road /ID# 280120

    Abilene, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center /ID# 279865

    Houston, Texas · Recruiting

  • Blue Ridge Cancer Care - Blacksburg /ID# 280115

    Blacksburg, Virginia · Recruiting

  • Fred Hutch Cancer Center /ID# 281451

    Seattle, Washington · Recruiting

  • Imelda Ziekenhuis /ID# 279333

    Bonheiden, Antwerpen, Belgium · Recruiting

  • Universitair Ziekenhuis Antwerpen /ID# 279334

    Edegem, Antwerpen, Belgium · Recruiting

  • Institut Jules Bordet /ID# 279406

    Anderlecht, Brussels Capital, Belgium · Recruiting

  • Cliniques Universitaires UCL Saint-Luc /ID# 279335

    Brussels, Brussels Capital, Belgium · Recruiting

  • Universitair Ziekenhuis Brussel /ID# 279535

    Jette, Brussels Capital, Belgium · Recruiting

  • Grand Hopital de Charleroi - Les Viviers /ID# 279336

    Charleroi, Hainaut, Belgium · Recruiting

  • Universite Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 280014

    Yvoir, Namur, Belgium · Recruiting

  • AZ Maria Middelares /ID# 280141

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • Universitair Ziekenhuis Leuven /ID# 279330

    Leuven, Vlaams-Brabant, Belgium · Recruiting

  • AZ-Delta. /ID# 279329

    Roeselare, West-Vlaanderen, Belgium · Recruiting

  • Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa /ID# 279572

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 279574

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • Beijing Hospital No. 2 /ID# 279666

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Friendship Hospital /ID# 279766

    Beijing, Beijing Municipality, China · Recruiting

  • Sun Yat-Sen University Cancer Center /ID# 279670

    Guangzhou, Guangdong, China · Recruiting

  • Zhujiang Hospital /ID# 279667

    Guangzhou, Guangdong, China · Recruiting

  • Guangxi Medical University Cancer Hospital /ID# 279707

    Nanning, Guangxi, China · Recruiting

  • Harbin Medical University Cancer Hospital /ID# 279961

    Harbin, Heilongjiang, China · Recruiting

  • Henan Cancer Hospital /ID# 279678

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital - Tongji Medical College /ID# 283649

    Wuhan, Hubei, China · Recruiting

  • Hubei Cancer Hospital /ID# 279687

    Wuhan, Hubei, China · Recruiting

  • Affiliated Hospital Of Jiangnan University(Wuxi Fourth People'S Hospital ) /ID# 280200

    Wuxi, Jiangsu, China · Recruiting

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.